Genomes and Genes
Affiliation: Boehringer Ingelheim
- ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?Frank Gillardon
CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
J Neurosci Methods 214:62-8. 2013..Since kinase inhibitors prevent autophosphorylation and refolding of the activation segment, we hypothesize that the antibody preferentially binds to the active conformation of LRRK2 under native conditions...
- Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicityF Gillardon
Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Birkendorfer Strasse 65, 88397 Biberach, Germany
Neuroscience 208:41-8. 2012..These findings indicate that enhanced neuroinflammation may contribute to neurodegeneration in Parkinson's disease patients carrying LRRK2 mutations...
- Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteinsC Schnack
Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Biberach an der Riss, Germany
Neuroscience 154:1450-7. 2008..Our data indicate that components of small GTPase signal transduction pathways may be directly targeted by alpha-synuclein oligomers which potentially leads to signaling deficits and neurodegeneration...
- Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitroF Gillardon
Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Birkendorfer St 65, 88397 Biberach an der Riss, Germany
Neuroscience 163:533-9. 2009..These findings suggest that the interaction between LRRK2 and EF1A may reciprocally modulate their physiological function...